

How to evaluate emerging technologies in cervical cancer

International Journal of Cancer

125, 2489-2496

DOI: [10.1002/ijc.24774](https://doi.org/10.1002/ijc.24774)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Comparison of Liquid-Based Cytology With Conventional Cytology for Detection of Cervical Cancer Precursors. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1757.	3.8	205
2	Trials comparing cytology with human papillomavirus screening. <i>Lancet Oncology, The</i> , 2009, 10, 935-936.	5.1	66
3	Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results. <i>Gynecologic Oncology</i> , 2010, 119, 98-105.	0.6	59
4	Cervical Cytology Biobanking in Europe. <i>International Journal of Biological Markers</i> , 2010, 25, 117-125.	0.7	21
5	Optional screening strategies for cervical cancer using standalone tests and their combinations among low- and medium-income populations in Latin America and Eastern Europe. <i>Journal of Medical Screening</i> , 2010, 17, 195-203.	1.1	12
6	Commercially available assays for multiplex detection of alpha human papillomaviruses. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 1139-1162.	2.0	108
7	Comparison of the clinical performance of carcinogenic HPV typing of the Linear Array and Papillocheck® HPV-screening assay. <i>Journal of Clinical Virology</i> , 2010, 47, 38-42.	1.6	26
8	Evaluation of the clinical performance of the Abbott RealTime High-Risk HPV for carcinogenic HPV detection. <i>Journal of Clinical Virology</i> , 2010, 48, 246-250.	1.6	20
9	Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. <i>Lancet Oncology, The</i> , 2010, 11, 1160-1171.	5.1	129
10	HPV-based cervical-cancer screening in China. <i>Lancet Oncology, The</i> , 2010, 11, 1112-1113.	5.1	28
11	The interface of population-based cancer registries and biobanks in etiological and clinical research – current and future perspectives. <i>Acta Oncologica</i> , 2010, 49, 1227-1234.	0.8	16
12	Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts. <i>Future Microbiology</i> , 2011, 6, 1083-1098.	1.0	121
13	Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. <i>Lancet, The</i> , 2011, 378, 1868-1873.	6.3	191
14	CIP2A expression is elevated in cervical cancer. <i>Cancer Biomarkers</i> , 2011, 8, 309-317.	0.8	27
15	Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavirus type 16. <i>Virology</i> , 2011, 421, 19-27.	1.1	23
16	Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2+3 in follow up biopsies and spontaneous regression of CIN2+3. <i>Gynecologic Oncology</i> , 2011, 123, 278-283.	0.6	45
17	DNA Cytometry Testing for Cervical Cancer Screening: Approaches and Reporting Standards for New Technologies. <i>Clinical Cancer Research</i> , 2011, 17, 6971-6972.	3.2	3
18	Comparison of Clinical and Analytical Performance of the Abbott RealTime High Risk HPV Test to the Performance of Hybrid Capture 2 in Population-Based Cervical Cancer Screening. <i>Journal of Clinical Microbiology</i> , 2011, 49, 1721-1729.	1.8	66

#	ARTICLE	IF	CITATIONS
19	Persistent Carcinoma in Cervical Cancer Screening: Non-Participation Is the Most Significant Cause. <i>Acta Cytologica</i> , 2011, 55, 433-437.	0.7	39
20	Human papillomavirus testing: the challenges of picking the right tools for the job. <i>Expert Review of Obstetrics and Gynecology</i> , 2011, 6, 643-653.	0.4	5
21	Genome-wide methylation profiling identifies hypermethylated biomarkers in high-grade cervical intraepithelial neoplasia. <i>Epigenetics</i> , 2012, 7, 1268-1278.	1.3	40
22	Inviting Patients to Read Doctors' Notes. <i>Annals of Internal Medicine</i> , 2012, 156, 608.	2.0	50
23	Screening for Cervical Cancer. <i>Annals of Internal Medicine</i> , 2012, 156, 604.	2.0	4
24	Defining Patient Complexity. <i>Annals of Internal Medicine</i> , 2012, 156, 607.	2.0	50
25	Defining Patient Complexity. <i>Annals of Internal Medicine</i> , 2012, 156, 606.	2.0	7
26	Human papillomavirus genotyping, human papillomavirus mRNA expression, and p16/Ki-67 cytology to detect anal cancer precursors in HIV-infected MSM. <i>Aids</i> , 2012, 26, 2185-2192.	1.0	70
27	Comparison of Seven Tests for High-Grade Cervical Intraepithelial Neoplasia in Women with Abnormal Smears: the Predictors 2 Study. <i>Journal of Clinical Microbiology</i> , 2012, 50, 1867-1873.	1.8	150
28	Estimation of disease prevalence, true positive rate, and false positive rate of two screening tests when disease verification is applied on only screen-positives: A hierarchical model using multi-center data. <i>Cancer Epidemiology</i> , 2012, 36, 153-160.	0.8	16
29	Claspin as a biomarker of human papillomavirus-related high grade lesions of uterine cervix. <i>Journal of Translational Medicine</i> , 2012, 10, 132.	1.8	18
30	Current guidelines for cervical cancer screening. <i>Journal of the American Academy of Nurse Practitioners</i> , 2012, 24, 417-424.	1.4	16
31	Nucleic Acid Tests for the Detection of Alpha Human Papillomaviruses. <i>Vaccine</i> , 2012, 30, F100-F106.	1.7	91
32	3q26 Amplification Is an Effective Negative Triage Test for LSIL: A Historical Prospective Study. <i>PLoS ONE</i> , 2012, 7, e39101.	1.1	10
33	Comparison of the AdvanSure Human Papillomavirus Screening Real-Time PCR, the Abbott RealTime High Risk Human Papillomavirus Test, and the Hybrid Capture Human Papillomavirus DNA Test for the Detection of Human Papillomavirus. <i>Annals of Laboratory Medicine</i> , 2012, 32, 201-205.	1.2	19
34	p16 ^{INK4a} immunocytochemistry versus human papillomavirus testing for triage of women with minor cytologic abnormalities. <i>Cancer Cytopathology</i> , 2012, 120, 294-307.	1.4	70
35	p16 ^{INK4a} "Is the future of cervical cancer screening rosy?". <i>Cancer Cytopathology</i> , 2012, 120, 291-293.	1.4	0
37	p16/Ki-67 dual staining in cervico-vaginal cytology: Correlation with histology, Human Papillomavirus detection and genotyping in women undergoing colposcopy. <i>Gynecologic Oncology</i> , 2012, 126, 198-202.	0.6	57

#	ARTICLE	IF	CITATIONS
38	Screening trial of human papillomavirus for early detection of cervical cancer in Santiago, Chile. <i>International Journal of Cancer</i> , 2013, 132, 916-923.	2.3	37
39	HPV genotype distribution according to severity of cervical neoplasia using the digene HPV genotyping LQ test. <i>Archives of Virology</i> , 2013, 158, 1143-1149.	0.9	9
40	<i>Pseudomonas aeruginosa</i> serology and risk for re-isolation in the EPIC trial. <i>Journal of Cystic Fibrosis</i> , 2013, 12, 147-153.	0.3	30
41	Increasing Adherence to Cervical Cancer Screening Guidelines. <i>Journal for Nurse Practitioners</i> , 2013, 9, 528-535.	0.4	5
42	A framework provided an outline toward the proper evaluation of potential screening strategies. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 639-647.	2.4	20
43	Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions. <i>The Cochrane Library</i> , 2021, 2021, CD008054.	1.5	67
44	Vaccination and Screening in Cervical Cancer Control and Prevention. , 2013, , 1175-1189.		0
45	Triage of women with minor abnormal cervical cytology: Meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types. <i>Cancer Cytopathology</i> , 2013, 121, 675-687.	1.4	36
46	Clinical Impact of the Analytical Specificity of the Hybrid Capture 2 Test: Data from the New Technologies for Cervical Cancer (NTCC) Study. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2901-2907.	1.8	26
47	High-Content Imaging in Cervical Cancer Screening. <i>Journal of Biomolecular Screening</i> , 2013, 18, 135-142.	2.6	2
48	Diagnostic Tests for the Detection of Human Papillomavirus-associated Cervical Lesions. <i>Current Pharmaceutical Design</i> , 2013, 19, 1358-1370.	0.9	9
49	Molecular Diagnosis of Human Papillomavirus Infections. , 2013, , .		3
50	HPV Diagnosis in Vaccination Era. , 2013, , .		0
51	Clinical application of DNA ploidy to cervical cancer screening: A review. <i>World Journal of Clinical Oncology</i> , 2014, 5, 931.	0.9	34
52	Performance of Self-Collected Cervical Samples in Screening for Future Precancer Using Human Papillomavirus DNA Testing. <i>Journal of the National Cancer Institute</i> , 2014, 107, dju400-dju400.	3.0	24
53	Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. <i>Nature Reviews Cancer</i> , 2014, 14, 395-405.	12.8	295
54	Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. <i>Lancet Oncology</i> , The, 2014, 15, 172-183.	5.1	508
55	Reply to triage of women with minor abnormal cervical cytology: Meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types. <i>Cancer Cytopathology</i> , 2014, 122, 77-78.	1.4	0

#	ARTICLE	IF	CITATIONS
56	Effectiveness of two strategies to follow-up ASC-US and LSIL screening results in The Netherlands using repeat cytology with or without additional hrHPV testing: a retrospective cohort study. <i>Cancer Causes and Control</i> , 2014, 25, 1141-1149.	0.8	9
57	Role of E6/E7 mRNA test in the diagnostic algorithm of HPV-positive patients showing ASCUS and LSIL: clinical and economic implications in a publicly financed healthcare system. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 137-150.	1.5	13
58	The predictive value of human papillomavirus testing for the outcome of patients conservatively treated for stage IA squamous cell cervical carcinoma. <i>Journal of Clinical Virology</i> , 2015, 70, 53-57.	1.6	8
59	Prevalence of human papillomavirus infection and genotyping for population-based cervical screening in developed regions in China. <i>Oncotarget</i> , 2016, 7, 62411-62424.	0.8	19
60	Clinical validation of hrHPV testing on vaginal and urine self-samples in primary cervical screening (cross-sectional results from the Papillomavirus Dumfries and Galloway "PaVDaG study"). <i>BMJ Open</i> , 2016, 6, e010660.	0.8	64
61	Biomarkers for Cervical Cancer Prevention Programs: The Long and Winding Road From Discovery to Clinical Use. <i>Journal of Lower Genital Tract Disease</i> , 2016, 20, 191-194.	0.9	7
62	Commercially available molecular tests for human papillomaviruses (HPV): 2015 update. <i>Journal of Clinical Virology</i> , 2016, 76, S3-S13.	1.6	105
63	Triage of HPV positive women in cervical cancer screening. <i>Journal of Clinical Virology</i> , 2016, 76, S49-S55.	1.6	236
64	VALGENT: A protocol for clinical validation of human papillomavirus assays. <i>Journal of Clinical Virology</i> , 2016, 76, S14-S21.	1.6	123
65	Molecular tests potentially improving HPV screening and genotyping for cervical cancer prevention. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 379-391.	1.5	55
66	Interobserver reproducibility of cytologic p16 ^{INK4a} /Ki67 dual immunostaining in human papillomavirus-positive women. <i>Cancer Cytopathology</i> , 2017, 125, 212-220.	1.4	25
67	Cytology versus HPV testing for cervical cancer screening in the general population. <i>The Cochrane Library</i> , 2017, 8, CD008587.	1.5	189
68	First-void urine: A potential biomarker source for triage of high-risk human papillomavirus infected women. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 216, 1-11.	0.5	27
69	The Value of a Novel Panel of Cervical Cancer Biomarkers for Triage of HPV Positive Patients and for Detecting Disease Progression. <i>Pathology and Oncology Research</i> , 2017, 23, 295-305.	0.9	10
70	Analytic and Diagnostic Performances of Human Papillomavirus E6/E7 mRNA Test on up-to 11-Year-Old Liquid-Based Cervical Samples. A Biobank-Based Longitudinal Study. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1480.	1.8	9
71	Biospecimens and Biobanking in Global Health. <i>Clinics in Laboratory Medicine</i> , 2018, 38, 183-207.	0.7	16
72	ANOVA model for network meta-analysis of diagnostic test accuracy data. <i>Statistical Methods in Medical Research</i> , 2018, 27, 1766-1784.	0.7	63
73	Characterization of JAK2 V617F (1849 G → T) Mutation in Cervical Cancer Related to Human Papillomavirus and Sexually Transmitted Infections. <i>Journal of Cancer Prevention</i> , 2018, 23, 82-86.	0.8	10

#	ARTICLE	IF	CITATIONS
74	VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples. <i>Journal of Clinical Virology</i> , 2018, 107, 52-56.	1.6	72
75	Liquid-based cytology: do ancillary techniques enhance detection of epithelial abnormalities?. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 159-169.	0.8	2
76	Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia (CIN2+): a systematic review and meta-analysis. <i>British Journal of Cancer</i> , 2019, 121, 954-965.	2.9	76
77	Long-term CIN3+ risk of HPV positive women after triage with FAM19A4/miR124-2 methylation analysis. <i>Gynecologic Oncology</i> , 2019, 154, 368-373.	0.6	32
78	Cervical Cancer Screening: Comparison of Conventional Pap Smear Test, Liquid-Based Cytology, and Human Papillomavirus Testing as Stand-alone or Cotesting Strategies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 474-484.	1.1	24
79	p16/Ki-67 co-expression associates high risk human papillomavirus persistence and cervical histopathology: a 3-year cohort study in China. <i>Oncotarget</i> , 2016, 7, 64810-64819.	0.8	17
80	Host chemokine signature as a biomarker for the detection of pre-cancerous cervical lesions. <i>Oncotarget</i> , 2018, 9, 18548-18558.	0.8	6
81	Diagnostic Accuracy of Conventional Cell Blocks Along with p16INK4 and Ki67 Biomarkers as Triage Tests in Resource-poor Organized Cervical Cancer Screening Programs. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 917-923.	0.5	4
82	Direct bisulphite conversion of cervical samples for DNA methylation analysis. <i>Epigenetics</i> , 2022, 17, 1173-1179.	1.3	6
83	Screening for Cervical Cancer. <i>Annals of Internal Medicine</i> , 2012, 156, 605.	2.0	6
84	Sample Preparation and Profiling: Biomarker Discovery in Body Fluids by Proteomics. <i>RSC Drug Discovery Series</i> , 2013, , 113-135.	0.2	0
85	Filogenia y oncogénesis del virus del papiloma humano: una aproximación translacional al descubrimiento de biomarcadores para la detección de lesiones precancerosas de cérvix. <i>Revista De La Academia Colombiana De Ciencias Exactas, Físicas Y Naturales</i> , 2019, 43, 351-365.	0.0	1
86	The effect of p16/Ki-67 and p16/mcm2 on the detection of cervical intraepithelial neoplasia: a prospective study from China. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 4101-4108.	0.5	1
87	Meta-analysis of agreement/concordance statistics in studies comparing self-vs clinician-collected samples for <sc>HPV</sc> testing in cervical cancer screening. <i>International Journal of Cancer</i> , 2022, 151, 308-312.	2.3	31
88	Comparative performance of the human papillomavirus test and cytology for primary screening for high-grade cervical intraepithelial neoplasia at the population level. <i>International Journal of Cancer</i> , 2022, 150, 1422-1430.	2.3	4
89	Validation of BD Onclarity HPV Assay on Vaginal Self-Samples versus Cervical Samples Using the VALHUDES Protocol. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 2177-2184.	1.1	11